Jane Liesveld, MD, Oncology, Rochester, NY, Highland Hospital

JaneLLiesveldMD

Oncology Rochester, NY

Hematologic Oncology

Professor of Medicine and Hematology/Oncology and an attending hematologist at the University of Rochester Medical Center

Dr. Liesveld is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Liesveld's full profile

Already have an account?

Education & Training

  • University of Rochester
    University of RochesterFellowship, Medical Oncology, 1987 - 1988
  • University of Rochester
    University of RochesterFellowship, Hematology, 1984 - 1987
  • Unity St Mary's CampusFellowship, Hematology, 1983 - 1984
  • University of Rochester
    University of RochesterResidency, Internal Medicine, 1980 - 1983
  • University of Iowa Carver College of Medicine
    University of Iowa Carver College of MedicineClass of 1980

Certifications & Licensure

  • IA State Medical License
    IA State Medical License 1981 - 2023
  • NY State Medical License
    NY State Medical License 1981 - 2021
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
  • Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Cancer-Related Distress and Unmet Needs Among Acute Myeloid Leukemia Survivors
    Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Increased Early Mortality after Fludarabine and Melphalan Conditioning with Peripheral Blood Grafts in Haploidentical SCT with Post-Transplant Cyclophosphamide
    Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic ...
    Jane L. Liesveld, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus o... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • 2012 Best of ASCO Chicago 
    American Society of Clinical Oncology(ASCO), Chicago, Illinois - 7/12/2012

Press Mentions

  • As Leukemia Evolves, Stem Cells Hold Keys to Newer Therapies
    As Leukemia Evolves, Stem Cells Hold Keys to Newer TherapiesAugust 29th, 2016

Grant Support

  • Substrata Interactions Of Normal And Leukemic Hematopoietic Stem CellsNational Cancer Institute2008–2009
  • Proteasome Inhibition In Myelodysplastic SyndromesNational Cancer Institute2005–2006
  • Progenitor Cell-Microenvironment InteractionsNational Heart, Lung, And Blood Institute1990–1994

Hospital Affiliations